Health In Tech gets two Nasdaq deficiency letters: audit committee makeup and sub-$1 bid price

Health In Tech, Inc.

• Oct 14, 2026 Nasdaq letter: Board is 2-of-4 independent and Audit Committee has only 2 members after Sanjay Shrestha resigned Aug 10, 2026.
• Breaches Nasdaq Rules 5605(b)(1) and 5605(c)(2)(A); cure period runs to the earlier of the next annual meeting or Aug 10, 2027.
• Annual meeting set for Nov 10, 2026, where Health In Tech expects to elect a new independent director and add them to the Audit Committee.
• Oct 12, 2026 letter: Class A stock (HIT) closed below $1.00 for 30 straight business days, violating Rule 5550(a)(2); 180-day cure ends April 12, 2027.
• Regaining the bid price requires 10 consecutive closes at $1.00+; company may use a reverse stock split, and a second 180-day period is possible.